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Preterm labor is a major clinical hazard causing both maternal and neonatal morbidity and mortality.
Paroxysmal supraventricular tachycardia (PSVT) complicated by preterm labor is rare. Of the many drugs
used to treat PSVT, only calcium channel blockers are tocolytics. Here, we present the case of a 29-year-
old female admitted to our ward with previously diagnosed PSVT and preterm labor at 31 weeks’ gestation
of her fourth pregnancy. Calcium channel blockers were administered and her uterine contractions
subsided. Afterwards, no side effects were noted and she suffered no further tachycardic attacks during
her pregnancy. She successfully delivered a full-term baby and received subsequent regular follow-up
at the outpatient clinic.
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Arrhythmias complicating pregnancy may threaten either
maternal or fetal well-being [1]. Due to recent advances in
cardiac surgery, supraventricular or ventricular arrhyth-
mias are now more frequently encountered in patients
of reproductive age [2]. There are worries about anti-
arrhythmic drugs and that maternal pro-arrhythmia may
occur with the use of Vaughan William Class 1 and 3 agents
[3,4]. Therefore, challenges to obstetricians include the
choice of anti-arrhythmic drugs to provide maternal symp-
tomatic relief and the avoidance of possible adverse effects
to the fetus.
Treatment plans become more complex if the arrhyth-
mia is associated with preterm labor. Betamimetics such as
ritodrine are the traditional first-line drugs for tocolysis, but
they may cause considerable undesirable maternal cardiac
effects [5]. King et al recently demonstrated that calcium
channel blockers are safe when used as tocolytics, based
on their review of 12 randomized controlled trials [6]. Here,
we report clinical experience with a pregnant woman who
had the complications of both paroxysmal supraventricular
tachycardia (PSVT) and preterm labor.
CASE PRESENTATION
A 29-year-old woman, gravida 3, para 0, aborta 2, with a
history of palpitation, shortness of breath, and cold sweats,
was first diagnosed with PSVT at our hospital on June 17,
1995, when she was discovered to be pregnant. She was first
seen at our obstetric department at 6 weeks’ gestation of her
third pregnancy on June 20, 1995, and received follow-up at
the outpatient clinic following multiple episodes of PSVT.
At 37 weeks’ gestation, cesarean delivery was performed
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due to progressive atrial tachycardia, and a healthy male
infant weighing 2,700 g was delivered. Maternal intraoper-
ative blood pressure was 90/70 to 115/75 mmHg, and
pulse rate was 130 to 162 bpm. Anesthesia was adminis-
tered by epidural induction. Apgar scores at 1 and 5 min-
utes were 5 and 7, respectively.
On April 20, 2001, the patient was readmitted to our
hospital at 22 weeks’ gestation of her fourth pregnancy
for PSVT control. During this pregnancy, she had suffered
from dyspnea, palpitation, orthopnea, leg edema, and cold
sweats since 6 weeks’ gestation. Symptoms were aggravat-
ed in the afternoon, especially in the supine position. Her
blood pressure was 116/74 mmHg and heart rate was 160
bpm. Immediate electrocardiography confirmed recurrent
PSVT. Cardiac echography showed a fraction shortening of
30%, trivial mitral regurgitation, septal hypokinesia, and a
small amount of pericardial effusion.
On June 18, 2001, she visited our clinic at 31 weeks’ ges-
tation complaining of regular cramping abdominal pain.
Fetal monitoring showed regular uterine contractions at
8-minute intervals with pressure tension of 50 mmHg and
a fetal heart beat averaging 150 bpm. We used nifedipine,
administered orally in doses of 10 mg, three times a day to
treat both atrial tachycardia and preterm labor. Fortunate-
ly, the contractions subsided and there was an obvious
improvement in symptoms, so she was discharged. At 36
weeks’ gestation, she delivered, by cesarean section, a
healthy male infant weighing 2,950 g, with Apgar scores
of 8 and 9 at 1 and 5 minutes, respectively. No complica-
tions except intraoperative hypotension were noted. Blood
pressure was 96/40 mmHg and pulse rate was 158 bpm
initially, and 120/62 mmHg and 128 bpm, respectively, post-
operatively. The postpartum period was uncomplicated.
DISCUSSION
Tawam et al reported that pregnancy is associated with
an increased risk of supraventricular tachycardia (SVT) [7].
Even during normal pregnancy, especially in the second tri-
mester, altered regional blood flow distribution, increased
cardiac output and left ventricular diameter, and myocardial
hypertrophy result in a maternal hyperhemodynamic status
to sustain fetal growth [8,9]. These physiologic adaptations
lead to the speculation that maternal arrhythmias are prone
to be prevalent during pregnancy or in labor [10–12].
The use of anti-arrhythmics during pregnancy may
cause immense concern regarding safety issues and is lim-
ited with regard to fetal well-being. Some reports illustrate
successful use of radiofrequency catheter ablation of supra-
ventricular arrhythmias [13]. Fortunately, in our patient,
symptoms subsided after nifedipine use and were con-
trolled long term with digoxin. Resolution of atrial tachy-
cardia during the first pregnancy was evident postpartum
in our patient, but recurred in a following pregnancy.
Various studies have found nifedipine to be at least as
effective as ritodrine and associated with fewer side effects
in suppressing preterm labor. One such study by Saade
et al reported that nifedipine was more effective than mag-
nesium sulfate in treating preterm labor [14]. Without en-
tering into the debate on which tocolytic drug is superior,
we make an early assumption that calcium blockers are
preferable to conventional tocolytic agents in cases of
preterm labor with PSVT. Verapamil is a calcium channel
blocker that has often been used in the management of
PSVT. Response has been described as excellent, with a
lack of maternal and fetal side effects [15]. Other authors
insist that caution should be exercised when using verapa-
mil since it has exacerbated systemic hypotension, con-
gestive heart failure, bradyarrhythmias, and ventricular
fibrillation. It also crosses the placenta and may result
in fetal bradycardia, heart block, depression of contracti-
lity, and hypotension [16]. Klein and Repke reported that
up to 96.7% of episodes of narrow-QRS SVT are convert-
ed to sinus rhythm within 1 to 2.5 minutes after adminis-
tration of intravenous verapamil [17]. However, to our
knowledge, there is little information on the management
of maternal tachycardia complicated by preterm labor.
Similarly, several tocolytic agents inhibit preterm labor,
among which betamimetics such as ritodrine have been
shown to decrease mortality rate, respiratory distress, and
result in a higher birth weight, compared to infants who do
not receive such treatment [18]. Nevertheless, when carefully
assessed, these betamimetics simultaneously resulted in
potentially serious complications that may aggravate the
maternal cardiac and metabolic condition [19].
Even though the efficacy of oral ritodrine has been chal-
lenged, many doctors prescribe it for arresting preterm
labor in an outpatient setting [20]. Calcium channel blockers
such as nifedipine and verapamil are currently used to treat
coronary artery disease and hypertension via smooth muscle
relaxation, making it more promising for the treatment of
uterine contraction and preterm labor [20].
All drugs have possible side effects. The role of calcium
channel blockers in preterm labor mandates further studies.
To the best of our knowledge, there are few reports on pre-
term labor in pregnant women with atrial tachycardias in
the English literature. Our use of calcium channel block-
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ers resolved two issues for this pregnant woman, preterm
labor and PSVT. Our case report serves to address the use
of calcium channel blockers as preferable first-line therapy
for maternal atrial tachycardias complicated by preterm
labor.
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